Guo An Liu
Direktor/Vorstandsmitglied bei Jumpcan Pharmaceutical Co. Ltd.
Profil
Guo An Liu is currently employed at Jumpcan Pharmaceutical Co. Ltd.
with the title of JUMPCAN PHARMACEUTICAL CO LTD.
Previously, Mr. Liu worked at Hubei Jumpcan Pharmaceutical Co., Ltd.
as a Member-Supervisory Board.
Aktive Positionen von Guo An Liu
| Unternehmen | Position | Beginn |
|---|---|---|
Jumpcan Pharmaceutical Co. Ltd.
 Jumpcan Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Hubei Jumpcan Pharmaceutical Co., Ltd., Jumpcan Pharmaceutical Co. Ltd. is a pharmaceutical company based in Taixing, China. The Chinese company offers a range of products including mouthwash, cough medicine, and pain relief ointments. The CEO of the company is Long Xiang Cao. Jumpcan Pharmaceutical Co. was acquired by Hubei Jumpcan Pharmaceutical Co., Ltd. from Jiangsu Jichuan Holdings Group Co. Ltd. on December 20, 2013 for $911.88 million. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Guo An Liu
| Unternehmen | Position | Ende |
|---|---|---|
| HUBEI JUMPCAN PHARMACEUTICAL CO., LTD. | Direktor/Vorstandsmitglied | 16.04.2018 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| HUBEI JUMPCAN PHARMACEUTICAL CO., LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Jumpcan Pharmaceutical Co. Ltd.
Jumpcan Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Hubei Jumpcan Pharmaceutical Co., Ltd., Jumpcan Pharmaceutical Co. Ltd. is a pharmaceutical company based in Taixing, China. The Chinese company offers a range of products including mouthwash, cough medicine, and pain relief ointments. The CEO of the company is Long Xiang Cao. Jumpcan Pharmaceutical Co. was acquired by Hubei Jumpcan Pharmaceutical Co., Ltd. from Jiangsu Jichuan Holdings Group Co. Ltd. on December 20, 2013 for $911.88 million. | Health Technology |